Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA.
Affiliation
Cellular and Molecular Pharmacology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, United Kingdom.Issue Date
2005-09-26
Metadata
Show full item recordAbstract
Recent studies have identified conserved missense mutations in PIK3CA, the gene encoding the catalytic phosphatidylinositol-3-kinase subunit p110alpha, in a variety of human cancers. Further investigation demonstrated that PIK3CA mutations lead to increased basal phosphatidylinositol-3-kinase activity, promoting cell growth and invasion [Samuels, Y., Diaz, L.A., Jr., Schmidt-Kittler, O., Cummins, J.M., Delong, L., Cheong, I., Rago, C., Huso, D.L., Lengauer, C., Kinzler, K.W., Vogelstein, B. and Velculescu, V.E. (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561-573]. A panel of commonly used colorectal cancer cell lines was screened for these PIK3CA mutations. Constitutive and IGF-1-stimulated phosphatidylinositol-3-kinase activity, signal response and duration were assessed. In the assays used no differences distinguished cells carrying PIK3CA mutations indicating that these mutations did not significantly alter growth factor stimulated or steady state phosphatidylinositol-3-kinase activity in normal cell culture conditions.Citation
Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA. 2005, 579 (23):5123-8 FEBS Lett.Journal
FEBS LettersDOI
10.1016/j.febslet.2005.07.096PubMed ID
16150444Type
ArticleLanguage
enISSN
0014-5793ae974a485f413a2113503eed53cd6c53
10.1016/j.febslet.2005.07.096
Scopus Count
Collections
Related articles
- PIK3CA gene mutations in breast carcinoma in Malaysian patients.
- Authors: Ching-Shian Leong V, Jabal MF, Leong PP, Abdullah MA, Gul YA, Seow HF
- Issue date: 2008 Dec
- Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.
- Authors: Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M
- Issue date: 2007 Feb
- Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population.
- Authors: Abubaker J, Bavi P, Al-Harbi S, Ibrahim M, Siraj AK, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS
- Issue date: 2008 Jun 5
- Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.
- Authors: Whyte DB, Holbeck SL
- Issue date: 2006 Feb 10
- The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1.
- Authors: Astanehe A, Finkbeiner MR, Hojabrpour P, To K, Fotovati A, Shadeo A, Stratford AL, Lam WL, Berquin IM, Duronio V, Dunn SE
- Issue date: 2009 Jun 25